Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 4/20 | 0.50 |
| ▸ | PLAT | P00750 | 8/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 5/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2910750 | 0.95 | FFAR1 (0.49) | FFAR1PLATCD274S1PR1S1PR5 | |
| SCHEMBL13117828 | 0.90 | FFAR1 (0.61) | FFAR1PLATCD274S1PR1S1PR5 | |
| SCHEMBL2907674 | 0.90 | FFAR1 (0.52) | FFAR1PLATCD274S1PR1S1PR5 | |
| SCHEMBL2023800 | 0.89 | FFAR1 (0.62) | FFAR1PLATCD274S1PR1S1PR5 | |
| SCHEMBL12579006 | 0.89 | FFAR1 (0.56) | FFAR1PLATCD274S1PR1S1PR5 | |
| SCHEMBL2022354 | 0.89 | FFAR1 (0.53) | FFAR1PLATCD274PDCD1 | |
| SCHEMBL12579167 | 0.89 | FFAR1 (0.48) | FFAR1PLATCD274S1PR1S1PR5 | |
| SCHEMBL12579169 | 0.88 | FFAR1 (0.55) | FFAR1PLATCD274S1PR1S1PR5 | |
| SCHEMBL2026089 | 0.86 | FFAR1 (0.55) | FFAR1PLATCD274S1PR1S1PR5 | |
| SCHEMBL12579164 | 0.85 | FFAR1 (0.61) | FFAR1PLATCD274S1PR1S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267775-A1 | OXADIAZOLIDINEDIONE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-10-21 | — | — | US | claimed |
| EP-2216330-A1 | OXADIAZOLIDINEDIONE COMPOUND | Astellas Pharma Inc. (JP) | 2010-08-11 | — | — | EP | claimed |
| US-20100267775-A1 | OXADIAZOLIDINEDIONE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-10-21 | — | — | US | disclosed |
| US-20100267775-A1 | OXADIAZOLIDINEDIONE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-10-21 | — | — | US | disclosed |
| EP-2216330-A1 | OXADIAZOLIDINEDIONE COMPOUND | Astellas Pharma Inc. (JP) | 2010-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267775-A1 | OXADIAZOLIDINEDIONE COMPOUND | GPR119, GLP1R, GPR4 | FFAR1 38/4885PLAT 3298/4885CD274 1333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.